Literature DB >> 12759802

Source monitoring improvement in patients with schizophrenia receiving antipsychotic medications.

Richard S E Keefe1, Margaret P Poe, Joseph P McEvoy, Adam Vaughan.   

Abstract

RATIONALE: The absence of a relationship between cognitive deficit treatment response and positive symptom treatment response is often assumed, and few data have shed light on this issue. Most of these data have been collected using standard neuropsychological measures, which are ill-designed to assess the types of neurocognitive disturbances associated with psychotic symptoms. This study investigates the effect of treatment on source monitoring performance and its relation to the reduction of certain psychotic symptoms associated with the inability to identify self-generated mental events, known as "autonoetic agnosia".
OBJECTIVES: To determine whether risperidone, olanzapine, and haloperidol were differentially effective in reducing autonoetic agnosia and whether changes in this aspect of cognition were related to reduction of specific symptoms of psychosis.
METHODS: From a cohort of 49 patients diagnosed with schizophrenia by DSM-IV criteria and randomly assigned to double-blind treatment with risperidone, olanzapine, or haloperidol, 16 patients were identified with symptoms believed to reflect autonoetic agnosia ("target symptoms") as assessed with the Schneiderian Symptom Rating Scale, and then evaluated during a baseline period, and then at 1, 2, and 3 weeks. Autonoetic agnosia was assessed as the ability of a patient to distinguish self-generated words from both experimenter-generated words and pictorially presented words.
RESULTS: Analysis of patients from all treatment groups found a significant reduction in the number of "target" Schneiderian symptoms. Discrimination for items from the self-generated and heard sources significantly improved with treatment, as did the number of self-generated items that patients remembered as coming from the heard source ("self-hear errors"). The correlation between improvement in recognition of self-generated items and reduction in target Schneiderian symptoms after 2 weeks of treatment suggested a modest relationship between symptom improvement and changes in autonoetic agnosia.
CONCLUSIONS: While the differences between medications were not statistically significant, antipsychotic medication in general was associated with improvements in symptoms and cognitive deficits that may underlie autonoetic agnosia. Improvement of autonoetic agnosia was a weak predictor of positive symptom improvement in a limited sample.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12759802     DOI: 10.1007/s00213-003-1476-0

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  25 in total

1.  A multinomial modeling analysis of the mnemonic benefits of bizarre imagery.

Authors:  D M Riefer; J N Rouder
Journal:  Mem Cognit       Date:  1992-11

Review 2.  Cognitive impairment as a target for pharmacological treatment in schizophrenia.

Authors:  M Davidson; R S Keefe
Journal:  Schizophr Res       Date:  1995-09       Impact factor: 4.939

Review 3.  Source monitoring.

Authors:  M K Johnson; S Hashtroudi; D S Lindsay
Journal:  Psychol Bull       Date:  1993-07       Impact factor: 17.737

4.  The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis.

Authors:  R S Keefe; S G Silva; D O Perkins; J A Lieberman
Journal:  Schizophr Bull       Date:  1999       Impact factor: 9.306

5.  Self-monitoring dysfunction and the schizophrenic symptoms of alien control.

Authors:  J D Stirling; J S Hellewell; N Quraishi
Journal:  Psychol Med       Date:  1998-05       Impact factor: 7.723

6.  The concordance between symptom information gathered from remitted schizophrenic patients and their relatives.

Authors:  M J Dixon; S King
Journal:  J Psychiatr Res       Date:  1995 Nov-Dec       Impact factor: 4.791

7.  Contrasts between patients with affective disorders and patients with schizophrenia on a neuropsychological test battery.

Authors:  T E Goldberg; J M Gold; R Greenberg; S Griffin; S C Schulz; D Pickar; J E Kleinman; D R Weinberger
Journal:  Am J Psychiatry       Date:  1993-09       Impact factor: 18.112

8.  Problem solving in schizophrenia: a specific deficit in planning ability.

Authors:  R G Morris; T Rushe; P W Woodruffe; R M Murray
Journal:  Schizophr Res       Date:  1995-02       Impact factor: 4.939

9.  The generalized pattern of neuropsychological deficits in outpatients with chronic schizophrenia with heterogeneous Wisconsin Card Sorting Test results.

Authors:  D L Braff; R Heaton; J Kuck; M Cullum; J Moranville; I Grant; S Zisook
Journal:  Arch Gen Psychiatry       Date:  1991-10

Review 10.  What are the functional consequences of neurocognitive deficits in schizophrenia?

Authors:  M F Green
Journal:  Am J Psychiatry       Date:  1996-03       Impact factor: 18.112

View more
  4 in total

Review 1.  A neuropsychiatric model of biological and psychological processes in the remission of delusions and auditory hallucinations.

Authors:  Mark van der Gaag
Journal:  Schizophr Bull       Date:  2006-08-11       Impact factor: 9.306

2.  Distinguishing familiarity-based from source-based memory performance in patients with schizophrenia.

Authors:  Anthony P Weiss; Donald C Goff; Margaret Duff; Joshua L Roffman; Daniel L Schacter
Journal:  Schizophr Res       Date:  2007-07-12       Impact factor: 4.939

3.  The effects of a subpsychotic dose of ketamine on recognition and source memory for agency: implications for pharmacological modelling of core symptoms of schizophrenia.

Authors:  Garry D Honey; Chris O'loughlin; Danielle C Turner; Edith Pomarol-Clotet; Philip R Corlett; Paul C Fletcher
Journal:  Neuropsychopharmacology       Date:  2006-02       Impact factor: 7.853

4.  Dissociable source-monitoring impairments in obsessive-compulsive disorder and schizophrenia.

Authors:  Layla Lavallé; Rémy Bation; Clément Dondé; Marine Mondino; Jérome Brunelin
Journal:  Eur Psychiatry       Date:  2020-05-14       Impact factor: 5.361

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.